Julie Adrian, European managing director of inVentiv Health Communications, outlines the greatest barriers preventing companies from engaging patients earlier in drug development and highlights the greatest benefits on offer to those that can successfully implement patient-centric drug discovery models.
A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
The UK, despite its size, is a biotech powerhouse. But a post-Brexit reality will focus on how the country manages to retain its power in uncertain times and without the backing of 27 other member states.
"Pharma is throwing the term precision medicine around but it still doesn't really understand what it will take to achieve it," according to the world's first chief precision medicine officer, BERG Health's Michael Kiebish. BERG is combining artificial intelligence and systems biology to analyze stacks of biological data.
Having clinical trial endpoints that are pragmatic and doable and a clear understanding of what the goalposts are for winning the FDA's approval to get a drug on the market will help decrease the uncertainty and drive investment, said Rakesh Marwah of Palo Alto Investors LLC, a Silicon Valley health care investment firm.
Authorities in England are viewing life-extending medicines as "simple commodities like groceries", says Wim Souverijns, general manager of Celgene UK & Ireland. Without a change in attitude, and if plans for a new Cancer Drugs Fund go ahead, companies could decide to relocate their studies from England, although plans for devolution could provide a chink of light for companies, says Souverijns.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.